Certificate of Analysis

Human Interleukin-29/Interferon Lambda 1, carrier-free

Catalog No: 11826-1

Lot No: Expiration: Size: 25 µg/vial

Description: Recombinant Human Interleukin-29/Interferon Lambda 1, carrier-free

Source: DNA sequence encoding the signal peptide from human CD33 was fused to the carboxyl terminally polyhistidine-tagged mature human IL-29 (Gly 20 - Thr 200) (Sheppard, P., et al. 2003, Nat. Immunol. 4(1):63 - 68). The chimeric protein was expressed in a mouse myeloma cell line, NS0.

Buffer: Phosphate buffered saline (PBS)

Reconstitution: It is recommended that sterile phosphate-buffered saline be added to the vial to prepare a working stock solution of no less than 100 μ g/ml. The carrier-free protein should be used immediately upon reconstitution to avoid losses in activity due to non-specific binding to the inside surface of the vial. For long term storage as a dilute solution, a carrier protein (e.g. 0.1% HSA or BSA) should be added to the vial.

Endotoxin: < 1 EU/µg

Molecular Weight: Based on N-terminal sequencing, the mature recombinant IL-29 starts at Gly 20 and has a calculated molecular mass of 21.4 kDa. As a result of glycosylation, the recombinant monomer migrates as an approximately 26-35 kDa protein in SDS-PAGE under reducing conditions.

Purity: > 95%

Synonyms: Hu-IL-29; Hu-IFN-λ1

Assay Used to Measure Bioactivity: Human HepG2 cells infected with encephalomyocarditis virus (Sheppard, P., *et al.* 2003, *Nature Immunol.* 4:63). The ED₅₀ for this effect is typically 1-5 ng/ml.

Product Information: IL-28A, IL-28B, and IL-29, also named interferon- λ 2 (IFN- λ 2), IFN- λ 3, and IFN- λ 1, respectively, are newly identified class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13% aa sequence identity) and type I IFN family (15 - 19% aa sequence identity). The genes encoding these three cytokines are localized to chromosome 19 and each is composed of multiple exons. The exon organization of these genes is also found in the IL-10 family genes but is distinct from the type I IFNs, which are encoded within a single exon. The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor β (IL-10 Rβ) and a novel IL-28 receptor α (IL-28 Rα, also known as IFN- λ R1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation. The phosphorylated STAT1 and STAT2 complex with IFN-regulatory factor 9 (IRF-9) to form the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex that is translocated to the nucleus. ISGF-3 binds to the IFN-stimulated response element (ISRE) present in the regulatory regions of the target genes. Human IL-29 cDNA encodes a 200 amino acid (aa) residue precursor protein with a putative 19 aa signal peptide and a 181 aa mature protein, which is a monomer in solution. It shares 67% and 69% aa sequence identity with human IL-28A and human IL-28B, respectively.

Shipping Conditions: Wet Ice

Physical State of Product During Shipping: Lyophilized

Storage Conditions/Comments: Upon receipt, the product should be kept at -20 to -70°C for retention of full activity. Upon reconstitution, this cytokine can be stored under sterile conditions at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer for three months without detectable loss of activity. Avoid repeated freeze-thaw cycles. For more information on protein handling, visit our Resource Library at www.pblassaysci.com.



References:

- 1. Vilcek, J., 2003, Nature Immunol. 4:8-9.
- 2. Sheppard, P., et al. 2003, Nature Immunol. 4:63-68.
- 3. Kotenko, S.V., et al. 2003, Nature Immunol. 4:69-77.

| Authorization | |
|--|-------|
| Released by: | Date: |
| Sold under license from Pestka Biomedical Laboratories, Inc. d/b/a PBL Assause in or administration to humans. Not for resale in original or any modifie | , , , |

in the preparation of any commercial product.